Insider · CIK 0001911592
Frazier Life Sciences XI, L.P.
Files at ATTO (Attovia Therapeutics, Inc.). First filing Aug 6, 2026, latest Aug 6, 2026.
In brief
Frazier Life Sciences XI, L.P. files SEC Form 4 as 10% owner at ATTO (Attovia Therapeutics, Inc.). Since Aug 6, 2026, Frazier Life Sciences XI, L.P. has reported 1 open-market buy worth $10.0M and 0 open-market sells worth $0, the latest filed on Aug 6, 2026.
A track record needs three past buys with six months of prices behind them; Frazier Life Sciences XI, L.P. has 0, so none is measured yet.
The newest scored trade: bought $10.0M of ATTO on Aug 6, 2026, filed Aug 6, 2026, scored 50 (moderate). In the last 12 months: 1 buy worth $10.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATTO: Attovia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Attovia Therapeutics, Inc. | $10.0M 588,235 shares | +11% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +1,749,192 | - | - | 1,824,541 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +1,590,175 | - | - | 3,414,716 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +1,189,940 | - | - | 4,604,656 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +961,322 | - | - | 5,565,978 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stock | +588,235 | $17.00 | $10.0M | 6,154,213 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivative | -16,250,000 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series A-2 Preferred Stockderivative | -14,772,727 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series B Preferred Stockderivative | -11,054,544 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series C Preferred Stockderivative | -8,930,685 | $0.00 | $0 | 0 | Aug 6, 2026 |
Questions about Frazier Life Sciences XI, L.P.
Answered from the filings on this page, as of the latest one.
Is Frazier Life Sciences XI, L.P. buying or selling?
In the last 12 months Frazier Life Sciences XI, L.P. reported 1 open-market buy worth $10.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $10.0M of ATTO on Aug 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Frazier Life Sciences XI, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Frazier Life Sciences XI, L.P. has 0.
Where does Frazier Life Sciences XI, L.P. file Form 4?
Frazier Life Sciences XI, L.P. has filed Form 4 at ATTO (Attovia Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.